Skip to content
DataLookout
Menu

ZENITHNCT07181109

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 1190 → 1226 locations
  2. Minor Trial sites expanded: 1153 → 1190 locations
    • Start date moved earlier from Sep 22, 2025 to Sep 6, 2025
  3. Minor Study sites: 1153 to 1190
  4. Notable Eligibility criteria expanded, about 11 words
    • Trial sites expanded: 1105 → 1153 locations
    • Primary and study completion dates: Sep 30, 2030 to Sep 23, 2030
  5. Minor Trial sites expanded: 995 → 1105 locationsv11
  6. Minor Trial sites expanded: 856 → 995 locationsv9
  7. Minor Trial sites expanded: 742 → 856 locationsv8
  8. Minor Trial sites expanded: 597 → 742 locationsv7
  9. Minor Trial sites expanded: 229 → 597 locationsv6
  10. Minor Study sites: 30 to 229
    • Primary and study completion dates: Oct 29, 2030 to Sep 30, 2030
    v4
  11. Minor Start date changed from estimate of Oct 24, 2025 to Sep 22, 2025v3
  12. Minor Study sites: 1 to 30v2
  13. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit)
Timeframe: Up to approximately 5 years

Secondary (5)

Change from Baseline in Mean Seated Office Systolic Blood Pressure (SBP) at Month 6
Time to First Occurrence of a Composite Endpoint of CV Death, Nonfatal MI, or Nonfatal Stroke
Composite Endpoint of CV Death and Total (First and Subsequent) HF Events (Hospitalization for HF or Urgent HF Visit)
Time to First Occurrence of Composite Endpoint of CV death, Nonfatal MI, Nonfatal Stroke, or Coronary Revascularization
Time to All-cause Death

Arms and interventions

Zilebesiran 300 mgExperimental

Participants will be administered 300 mg zilebesiran subcutaneously (SC) once every 6 months as add-on therapy to their standard of care antihypertensive medications.

PlaceboPlacebo comparator

Participants will be administered placebo SC once every 6 months as add-on therapy to their standard of care antihypertensive medications.

Drugs: Zilebesiran, Placebo

Sites

1,226 sites in 35 countries

United States 273, China 89, Poland 71, Argentina 66, Brazil 52, Germany 50, United Kingdom 49, Spain 45, Bulgaria 42, Japan 40, India 38, Canada 35, South Africa 31, Czechia 29, Hungary 29, Romania 25, South Korea 25, Italy 23, Greece 21, Belgium 20, Australia 19, Colombia 19, Portugal 19, Slovakia 16, Taiwan 13, France 12, Netherlands 11, Austria 10, Serbia 10, Turkey (Türkiye) 10, Chile 9, Denmark 8, New Zealand 7, Mexico 6, Sweden 4